866-997-4948(US-Canada Toll Free)

PharmaPoint: Obesity - Canada Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 111 Pages

PharmaPoint: Obesity - Canada Drug Forecast and Market Analysis to 2022

Summary

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The projected drivers of sales growth include the launch of more effective drugs for the obese population and the gradual shift in attitudes towards the treatment of obesity and consequently treatment regimen for the clinical management of the condition. The Canadian market is a severely underserved market, with Xenical as the sole therapy for chronic weight management.

Scope

- Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Canada from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Canada Obesity market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in Canada.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 19
4.1 Treatment Overview 19
4.2 Canada 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 25
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 32
5.3 Product Profiles: Drugs 34
5.3.1 Xenical (orlistat) 34
5.3.2 Qsymia (phentermine-topiramate) 37
5.3.3 Belviq (lorcaserin) 43
6 Opportunity and Unmet Need 48
6.1 Overview 48
6.2 A Drug with Greater Than 10% Average Weight Loss 49
6.2.1 Unmet Need 49
6.2.2 Gap Analysis 50
6.2.3 Opportunity 51
6.3 A Drug with Increased Safety and Tolerability 51
6.3.1 Unmet Need 51
6.3.2 Gap Analysis 52
6.3.3 Opportunity 52
6.4 Reimbursement by Private and Public Payers 52
6.4.1 Unmet Need 52
6.4.2 Gap Analysis 54
6.4.3 Opportunity 54
6.5 Increased Physician Education 54
6.5.1 Unmet Need 54
6.5.2 Gap Analysis 55
6.5.3 Opportunity 55
6.6 Increased Drug-Treatment Rate 56
6.6.1 Unmet Need 56
6.6.2 Gap Analysis 56
6.6.3 Opportunity 57
6.7 Improved Guidelines 57
6.7.1 Unmet Need 57
6.7.2 Gap Analysis 58
6.7.3 Opportunity 58
6.8 Improved Approach to Diagnosis 58
6.8.1 Unmet Need 58
6.8.2 Gap Analysis 59
6.8.3 Opportunity 59
7 Pipeline Assessment 60
7.1 Overview 60
7.2 Promising Drugs in Clinical Development 63
7.2.1 Contrave 66
7.2.2 Victoza (liraglutide) 71
7.2.3 Empatic 76
8 Market Outlook 81
8.1 Canada 82
8.1.1 Forecast 82
8.1.2 Key Events 86
8.1.3 Drivers and Barriers 87
9 Appendix 89
9.1 Bibliography 89
9.2 Abbreviations 96
9.3 Research Methodology 98
9.4 Forecasting Methodology 98
9.4.1 Percent Drug-Treated Obesity Patients 99
9.4.2 Drugs Included in Each Therapeutic Class 99
9.4.3 Launch and Patent Expiry Dates 100
9.4.4 General Pricing Assumptions 100
9.4.5 Individual Drug Assumptions 101
9.4.6 Generic Erosion 103
9.4.7 Pricing of Pipeline Agents 103
9.5 Physicians, Specialists, and Payers Included in This Study 104
9.6 About the Authors 107
9.6.1 Analysts 107
9.6.2 Therapy Director - CVMD and Infectious Disease 108
9.6.3 Director - Medical Devices 108
9.6.4 Global Head of Healthcare 109
9.7 About GlobalData 110
9.8 Disclaimer 110

List of Table

1.1 List of Tables
Table 1: Target Pathways in the Treatment of Obesity 17
Table 2: Symptoms of Obesity 18
Table 3: Treatment Guidelines for Obesity 22
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 23
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 24
Table 6: Bariatric Treatment Attributes 31
Table 7: Leading Drug Treatments for Obesity, 2013 32
Table 8: Marketed Obesity Treatment Devices by Type 33
Table 9: Product Profile - Xenical 35
Table 10: Xenical SWOT Analysis, 2013 37
Table 11: Product Profile - Qsymia 39
Table 12: Qsymia SWOT Analysis, 2013 43
Table 13: Product Profile - Belviq 45
Table 14: Belviq SWOT Analysis, 2013 47
Table 15: Unmet Need and Opportunity in Obesity 49
Table 16: Endpoint Analysis of Clinical Trials Conducted in Obesity, 2013 62
Table 17: Obesity - Phase II-III Pipeline, 2013 63
Table 18: Comparison of Therapeutic Classes in Development for Obesity, 2013 65
Table 19: Obesity Treatment Pipeline Devices by Type 65
Table 20: Product Profile - Contrave 67
Table 21: Contrave SWOT Analysis, 2013 70
Table 22: Product Profile - Victoza 72
Table 23: Victoza SWOT Analysis, 2013 76
Table 24: Product Profile - Empatic 77
Table 25: Empatic SWOT Analysis, 2013 80
Table 26: Sales Forecasts ($) for Obesity in Canada, 2012-2022 84
Table 27: Events Impacting Sales for Obesity in Canada, 2012-2022 86
Table 28: Obesity Market in Canada - Drivers and Barriers, 2012-2022 87
Table 29: Key Launch Dates 100
Table 30: Key Patent Expiries 100

List of Chart

1.2 List of Figures
Figure 1: Treatment Algorithm for Obesity 21
Figure 2: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Canada, 2012-2022 25
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012-2022 64
Figure 4: Sales for Obesity in Canada by Drug Class, 2012-2022 85

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *